Estrace vs. Bijuve

See how Estrace and Bijuve compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Estrace is an estrogen-only tablet that can be paired with a separate progestogen, while Bijuve combines estradiol and progesterone in one daily capsule for women with a uterus.

  • Estrace offers several tablet strengths and dosing schedules, while Bijuve comes in just two fixed-dose capsule strengths taken once a day.

  • Estrace has been available since 1975 and typically costs far less out of pocket than Bijuve, a newer combination product approved in 2018.

Estrace vs. Bijuve Drug Summary

Estrace

Estrace is an oral estrogen (estradiol) tablet approved for hot flashes, vaginal atrophy, hypoestrogenism, and prevention of postmenopausal osteoporosis. It is usually taken once daily at doses between 0.5 mg and 2 mg, with higher three-times-daily doses used for other approved conditions.

Bijuve

Bijuve is a combination oral capsule containing bioidentical estradiol and progesterone, approved for moderate to severe hot flashes in menopausal women who still have a uterus. It is taken once daily as a single fixed-dose capsule, available in two strengths.

Estrace vs. Bijuve Side Effects

Estrace

Most common
Nausea (NQ)
Abdominal cramping/bloating (NQ)
Headache (NQ)
Edema (NQ)

Bijuve

Most common
Breast tenderness (up to 10.4%)
Headache (up to 3.4%)
Vaginal bleeding (up to 3.4%)
Vaginal discharge (up to 3.4%)

Estrace vs. Bijuve Dosage

Estrace

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 10 mg three times daily At the start
Maximum dose 10 mg three times daily Same as starting
Dose changes None Fixed dose

Bijuve

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.5 mg/100 mg once daily At the start
Maximum dose 1 mg/100 mg once daily If needed
Dose changes 1 increase As tolerated

Estrace vs. Bijuve Indications

Estrace

Estrace is FDA-approved for a broad set of estrogen-related conditions, from hot flashes and vaginal atrophy to low estrogen after ovarian failure. It is also approved for preventing osteoporosis and for palliative treatment of certain hormone-sensitive cancers.

  • Moderate to severe hot flashes of menopause

  • Vaginal dryness and vulvar/vaginal atrophy

  • Low estrogen from ovarian failure, hypogonadism, or castration

  • Prevention of osteoporosis after menopause

Bijuve

Bijuve has a single FDA-approved use: treating moderate to severe hot flashes in menopausal women who still have a uterus. It is not approved for vaginal atrophy, osteoporosis prevention, or use in women without a uterus.

  • Moderate to severe vasomotor symptoms (hot flashes) of menopause

  • For women who have a uterus and need progestogen protection

  • Not approved for women without a uterus

  • Not approved for vaginal atrophy or osteoporosis prevention

Estrace vs. Bijuve Pros and Cons

Estrace

Estrace is an estrogen-only tablet with decades of clinical use and several dosing options, but it requires an added progestogen for women with a uterus to protect against endometrial cancer. It generally costs far less than newer combination products, though coverage still varies by insurance plan.

Pros

  • Available in multiple tablet strengths for flexible dosing

  • FDA-approved for a wider range of conditions, including osteoporosis prevention and certain cancers

  • Long track record of use dating back to 1975

Cons

  • Estrogen-only formula requires a separate progestogen for women with a uterus

  • Higher-dose regimens require dosing three times a day

  • 2 mg tablet contains tartrazine dye, which can trigger allergic reactions in some people

Bijuve

Bijuve packages bioidentical estradiol and progesterone into one capsule, simplifying treatment for women with a uterus who need both hormones. Its narrower approval and much higher price reflect its more recent entry into the market.

Pros

  • Combines estrogen and progesterone in a single daily capsule, no separate progestogen needed

  • Simple one-capsule-a-day dosing with only two strength options

  • Uses bioidentical micronized progesterone alongside bioidentical estradiol

Cons

  • Only approved for women who have a uterus

  • Approved for hot flashes only, not vaginal atrophy or osteoporosis prevention

  • Roughly $257 to $351 per month, substantially more than Estrace

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.